Form D · Pharmaceuticals
Kamal Therapeutics, Inc.
Hingham, MA · CIK 0001880064
Offering snapshot reported Nov 24, 2025 · SEC filing
- Reported sold
- $13.8M Offering amount: $17.3M
- Investors reported
- 41 Form D · investor count
- Minimum accepted
- $0 Reported outside-investor minimum
- First sale
- Nov 10, 2025 As reported in this filing
What changed?
Latest filing versus its linked predecessor, where available.
No comparable changes in the displayed metrics.
Filing history
Scroll to see all columns →
| Filed | Filing type | Reported sold | Change vs linked filing | Investors | Source |
|---|---|---|---|---|---|
| Nov 24, 2025 | Initial | $13,807,138 | No comparison | 41 | SEC filing |
| Oct 11, 2022 | Amendment | $9,943,000 | $5,626,000vs Aug 27, 2021 | 37 | SEC filing |
| Aug 27, 2021 | Initial | $4,317,000 | No comparison | 25 | SEC filing |
Offering details
- Securities
- Equity
- Exemptions
- 06b
- Duration over one year
- No
- Business combination
- No
- Sales commissions
- $0
- Finders' fees
- $0
- Form D file number
- 021-564798
Source: Form D, filed Nov 24, 2025. Minimum accepted may differ from a standard advertised minimum.
Fund connections
No matching detailed fund disclosure was found in the latest imported ADV filings. This does not establish that the issuer has no adviser.
People & organizations
Current and past Form D appearances. These existing records do not establish a person's current role or uniquely identify them across issuers.
| Name | Reported role |
|---|---|
| Mark De Souza | Director, Executive |
| Hal Landy | Director |
| Joff Masukawa | Director |
| John Parker | Director |
| Deborah Ramsdell | Director, Executive |
| Philip Reilly | Director |
| Alexander Silver | Director |
Issuer details
Industry: Pharmaceuticals (See others in industry)
Address:
66 Clubhouse Drive
Hingham, MA, 02043
Phone: 857 222 4653
Hingham, MA, 02043
Phone: 857 222 4653